Related Experiment Video

Updated: Aug 8, 2026

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 19, 2013

Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels

Ester Fonsatti1, Maresa Altomonte, Maria Rita Nicotra

  • 1Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientific, Aviano 33081, Italy.

Oncogene
|October 7, 2003
PubMed

Insights

Endoglin (CD105) is a key surface molecule on endothelial cells and is a promising target for anti-angiogenic cancer therapies. Its expression on tumor blood vessels and in circulation has prognostic value and potential for imaging.

Area of Science:

  • Oncology
  • Vascular Biology
  • Biochemistry

Background:

  • Endoglin (CD105) is a cell membrane glycoprotein primarily found on endothelial cells.
  • CD105 is overexpressed on tumor-associated vascular endothelium.
  • It plays a role in vascular development and remodeling as part of the TGF-beta receptor complex.

Purpose of the Study:

  • To explore endoglin (CD105) as a vascular target for anti-angiogenic cancer therapy.
  • To investigate the prognostic significance of CD105 quantification in cancer.
  • To assess the utility of CD105 in tumor imaging and anti-angiogenic strategies.

Main Methods:

  • Utilizing CD105 staining to quantify intratumoral microvessel density.
  • Measuring circulating soluble CD105 levels.
  • Employing animal models to evaluate CD105's role in tumor imaging and therapy.

Main Results:

  • CD105 is a significant surface molecule on endothelial cells with therapeutic potential.
  • Quantification of CD105 shows prognostic significance in certain cancers.
  • Animal studies demonstrate CD105's utility in tumor imaging and anti-angiogenic therapy.

Conclusions:

  • Endoglin (CD105) represents a crucial target for developing novel anti-angiogenic cancer treatments.
  • CD105-based diagnostics and therapeutics hold promise for improving cancer patient outcomes.

More Related Videos

Isolation and Culture Expansion of Tumor-specific Endothelial Cells10:15

Isolation and Culture Expansion of Tumor-specific Endothelial Cells

Published on: October 14, 2015

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-107:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...